cardiology careers collections past issues search home
     

J Am Coll Cardiol, 2008; 52:1957-1967, doi:10.1016/j.jacc.2008.09.010
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Daemen, J.
PubMed
Right arrow Articles by Daemen, J.
Related Collections
Right arrowRelated Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Multivessel Coronary Revascularization in Patients With and Without Diabetes Mellitus

3-Year Follow-Up of the ARTS-II (Arterial Revascularization Therapies Study–Part II) Trial

Joost Daemen, MD*, Karl Heinz Kuck, MD{dagger}, Carlos Macaya, MD{ddagger}, Victor LeGrand, MD§, Maarten Vrolix, MD||, Didier Carrie, MD, Imad Sheiban, MD#, Maarten Jan Suttorp, MD**, Pascal Vranckx, MD{dagger}{dagger}, Tessa Rademaker, MSc{ddagger}{ddagger}, Dick Goedhart, PhD{ddagger}{ddagger}, Monique Schuijer, PhD{ddagger}{ddagger}, Kristel Wittebols, MSc§§, Nathalie Macours, PhD§§, Hans Peter Stoll, MD§§, Patrick W. Serruys, MD, PhD*,* on behalf of the ARTS-II Investigators

* Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
{dagger} Hospital St. Georg, Hamburg, Germany
{ddagger} Hospital Clinico San Carlos, Madrid, Spain
§ CHU Sart Tilman, Liege, Belgium
|| Ziekenhuis Oost Limburg, Genk, Belgium
CHY Popital de Rangueil, Toulouse, France
# Azienda Ospedaliera San Giovanni Batista, Torino, Italy
** Sint Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands
{dagger}{dagger} Hospital Virga Jesse, Hasselt, Belgium
{ddagger}{ddagger} Cardialysis B.V., Rotterdam, the Netherlands
§§ Cordis Clinical Research Europe, Waterloo, Belgium

Manuscript received June 16, 2008; revised manuscript received August 14, 2008, accepted September 2, 2008.

* Reprint requests and correspondence: Prof. Patrick W. Serruys, Thoraxcenter, Ba-583, s-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands (Email: p.w.j.c.serruys{at}erasmusmc.nl).

Objectives: The purpose of this study was to assess the 3-year outcome of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients who had multivessel coronary artery disease with and without diabetes mellitus.

Background: The optimal method of revascularization in diabetic patients remains in dispute.

Methods: The ARTS-II (Arterial Revascularization Therapies Study–Part II) trial is a single-arm study (n = 607) that included 159 diabetic patients treated with SES whose 3-year clinical outcome was compared with that of the historical diabetic and nondiabetic arms of the randomized ARTS-I trial (n = 1,205, including 96 diabetic patients in the CABG arm and 112 in the PCI arm).

Results: At 3 years, among nondiabetic patients, the incidence of the primary composite of death, CVA, myocardial infarction (MI), and repeat revascularization (major adverse cardiac and cerebrovascular events [MACCE]), was significantly lower in ARTS-II than in ARTS-I PCI (adjusted odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.26 to 0.64) and similar to ARTS-I CABG. The ARTS-II patients were at significantly lower risk for death, CVA, and MI as compared with both the ARTS-I PCI (adjusted OR: 0.55; 95% CI: 0.34 to 0.91) and ARTS-I CABG patients (adjusted OR: 0.56; 95% CI: 0.35 to 0.92). Among diabetic patients, the incidence of MACCE in ARTS-II was similar to that of both PCI and CABG in ARTS-I. Conversely, the incidence of death, CVA, and MI was significantly lower in ARTS-II than in ARTS-I PCI (adjusted OR: 0.67; 95% CI: 0.27 to 1.65) and was similar to that of ARTS-I CABG.

Conclusions: At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and more efficacious than PCI using bare-metal stents, irrespective of the diabetic status of the patient. Hence, PCI using SES appears to be a valuable alternative to CABG for both diabetic and nondiabetic patients.

Key Words: coronary stents • sirolimus-eluting stent • diabetes • all-comers • coronary artery bypass graft surgery

Abbreviations and Acronyms
  BMS = bare-metal stent(s)
  CABG = coronary artery bypass graft surgery
  CI = confidence interval
  CK-MB = creatine kinase-myocardial band
  CVA = cerebrovascular accident
  DES = drug-eluting stent(s)
  MACCE = major adverse cardiac and cerebrovascular event(s)
  MI = myocardial infarction
  OR = odds ratio
  PCI = percutaneous coronary intervention
  SES = sirolimus-eluting stent(s)


Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A32. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Journal Watch CardiologyHome page
Drug-Eluting Stents vs. Coronary Artery Bypass Grafts in Patients with Diabetes
Journal Watch Cardiology, December 24, 2008; 2008(1224): 3 - 3.
[Full Text]



 
  cardiology careers collections past issues search home